LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

463.98 -1.48

Buy Sell

Overview

Share price change

24h

Current

Min

457.01

Max

464.63

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+51.83% upside

Dividends
By Dow Jones
Next Earnings	19 lut 2026

Market Stats
By TradingEconomics
Market Cap	1.9B 11B
Previous open	465.46
Previous close	463.98

News Sentiment

By Acuity

50%

148 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 lut 2026, 22:17 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 lut 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 lut 2026, 23:48 UTC

Market Talk

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16 lut 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16 lut 2026, 23:20 UTC

Acquisitions, Mergers, Takeovers

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16 lut 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16 lut 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16 lut 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Bar Very High For Asset Deals

16 lut 2026, 22:47 UTC

Acquisitions, Mergers, Takeovers

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16 lut 2026, 22:35 UTC

Market Talk

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16 lut 2026, 22:02 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 lut 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16 lut 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16 lut 2026, 21:48 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: China's Economy Resilient; India Continues to Outperform

16 lut 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16 lut 2026, 21:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16 lut 2026, 21:47 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16 lut 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16 lut 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16 lut 2026, 21:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Interim Dividend Represents 60% Payout Ratio

16 lut 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16 lut 2026, 21:45 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16 lut 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16 lut 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16 lut 2026, 21:42 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16 lut 2026, 21:42 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16 lut 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

51.83% upside

12 Months Forecast

Average 705.56 USD 51.83%

High 964 USD

Low 570 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

148 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.